We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Deals J&J Setback on Dapoxetine Development
FDA Deals J&J Setback on Dapoxetine Development
November 4, 2005
The FDA has declared Johnson & Johnson’s (J&J) experimental premature ejaculation (PE) drug dapoxetine “not approvable,” dealing a potentially significant setback to the firm’s pipeline, analysts said.